MACROTEC
LOE ApproachingBLAINJECTIONINJECTABLE
Approved
Feb 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MACROTEC is an injectable biologic approved by Bracco in 1976 with a BLA regulatory pathway. The product's specific mechanism of action, indications, and pharmacologic class are undisclosed, limiting clinical characterization. As an established injectable, it likely serves a chronic or acute care indication requiring parenteral administration.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team contraction or transition to generic/follow-on positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MACROTEC currently shows zero linked job postings, reflecting its mature lifecycle status and approaching LOE. Career opportunities are concentrated in commercial and market access functions focused on competitive positioning, pricing optimization, and managed care strategy rather than growth initiatives.
Brand ManagerProduct Manager
Worked on MACROTEC at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.